Impax Laboratories Inc. (IPXL)
-NasdaqGS 18.85 0.00(0.00%) 4:00PM EDT
| Prev Close: | 18.85 |
|---|
| Open: | 18.80 |
|---|
| Bid: | 18.12 x 400 |
|---|
| Ask: | 19.00 x 2000 |
|---|
| 1y Target Est: | 18.35 |
|---|
| Beta: | 1.2 |
|---|
| Next Earnings Date: | 31-Jul-13 |
|---|
| Day's Range: | 18.80 - 18.96 |
|---|
| 52wk Range: | 14.41 - 27.25 |
|---|
| Volume: | 492,802 |
|---|
| Avg Vol (3m): | 1,060,920 |
|---|
| Market Cap: | 1.25B |
|---|
| P/E (ttm): | 8.63 |
|---|
| EPS (ttm): | 2.18 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Does Restless Legs Syndrome Really Shorten Life Span?at Motley Fool(Mon, Jun 17)
- Supreme Court decision on generics hits Actavis, but few other drug firmsat MarketWatch(Mon, Jun 17)
- Impax Reduces WorkforceZacks(Thu, Jun 6)
- Filthy Pharma: Justice Department Taking "Especially Hard Look" At Manufacturing Plantsat Forbes(Thu, Jun 6)
- Bernstein Liebhard LLP Announces An Investigation Concerning Impax Laboratories, Inc.PR Newswire(Thu, Jun 6)
- Impax Labs to Cut Jobsat Motley Fool(Wed, Jun 5)
- Endo Health to slash 15 pct jobs, looks to sell some assetsat Reuters(Wed, Jun 5)
- Impax Labs cuts 110 manufacturing and sales jobsAP(Wed, Jun 5)
- Impax cuts 110 jobs, expects to save $15 millionReuters(Wed, Jun 5)
- Impax cuts 110 jobs, expects to save $15 mlnat Reuters(Wed, Jun 5)
- Impax Fires 110 Workers as Manufacturing Shifts to Taiwanat Bloomberg(Wed, Jun 5)
- IMPAX LABORATORIES INC Files SEC form 8-K, Costs Associated with Exit or Disposal Activities, Financial Statements anEDGAR Online(Wed, Jun 5)
- Impax Laboratories Announces Reduction in WorkforceBusiness Wire(Wed, Jun 5)
- Avanir Pharmaceuticals Builds A Pipeline In A Pillat Seeking Alpha(Mon, Jun 3)
- Impax Laboratories to Present at the Jefferies Global Healthcare ConferenceBusiness Wire(Mon, Jun 3)
Key Statistics
| Forward P/E (1 yr): | 32.50 |
|---|
| P/S (ttm): | 2.09 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 0.21 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 0.05 |
|---|
| Mean Recommendation*: | 2.8 |
|---|
| PEG Ratio (5 yr expected): | 5.81 |
|---|
Business Summary
Impax Laboratories, Inc., a specialty pharmaceutical company, engages in the development, manufacture, and marketing of bioequivalent pharmaceutical products; and development and marketing of branded products.
View More